X4 Pharmaceuticals (NASDAQ:XFOR) Posts Earnings Results, Beats Expectations By $0.05 EPS

Posted by Brian Himes on Aug 6th, 2026

X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05, Zacks reports. X4 Pharmaceuticals had a negative return on equity of 94.90% and a negative net margin of 1,106.30%.

X4 Pharmaceuticals Trading Up 0.5%

Shares of XFOR traded up $0.02 during mid-day trading on Thursday, hitting $4.17. The company had a trading volume of 447,777 shares, compared to its average volume of 545,007. X4 Pharmaceuticals has a 1-year low of $1.35 and a 1-year high of $4.83. The business’s 50-day simple moving average is $4.02 and its 200-day simple moving average is $3.94. The stock has a market cap of $393.31 million, a PE ratio of -0.92 and a beta of 0.37. The company has a quick ratio of 9.98, a current ratio of 10.18 and a debt-to-equity ratio of 0.45.

Analyst Upgrades and Downgrades

XFOR has been the topic of a number of recent research reports. Leerink Partners started coverage on shares of X4 Pharmaceuticals in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 target price on the stock. Weiss Ratings raised shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. Finally, Wells Fargo & Company initiated coverage on X4 Pharmaceuticals in a report on Friday, July 10th. They set an “overweight” rating and a $11.00 price target on the stock. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $9.70.

Check Out Our Latest Analysis on XFOR

Insider Activity

In other news, CFO David Kirske sold 8,543 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $4.26, for a total transaction of $36,393.18. Following the completion of the sale, the chief financial officer directly owned 167,750 shares in the company, valued at $714,615. This represents a 4.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.13% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On X4 Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Virtu Financial LLC purchased a new stake in shares of X4 Pharmaceuticals during the 4th quarter worth about $90,000. Susquehanna Portfolio Strategies LLC acquired a new position in X4 Pharmaceuticals during the fourth quarter valued at approximately $173,000. Man Group plc acquired a new position in X4 Pharmaceuticals during the fourth quarter valued at approximately $97,000. Balyasny Asset Management L.P. purchased a new stake in X4 Pharmaceuticals during the fourth quarter worth approximately $258,000. Finally, Braidwell LP purchased a new stake in X4 Pharmaceuticals during the fourth quarter worth approximately $13,476,000. 72.03% of the stock is owned by institutional investors and hedge funds.

About X4 Pharmaceuticals

(Get Free Report)

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.